What patient assistance does fintepla offer?

How does Fintepla's patient support program work?

Fintepla offers a patient assistance program that covers the cost of the drug for eligible patients who lack insurance coverage or whose insurance does not pay for it. The program also provides support navigating insurance coverage, prior authorizations, and reimbursement issues.

What eligibility rules apply to the program?

Patients must have a confirmed diagnosis of Dravet syndrome, be a U.S. resident, and meet income guidelines that are not publicly disclosed. The company does not accept Medicare, Medicaid, or any government-funded insurance.

How does Fintepla compare with other patient programs?

Many similar orphan drugs offer free drug or copay assistance through foundations or manufacturer programs. Fintepla's program is similar in structure but excludes government insurance entirely, which is common for drugs priced in the annual range of $30,000–$100,000.

When does Fintepla's exclusivity expire?

Fintepla's composition-of-matter patent expires in 2033. The company has filed several method-of-use patents that could extend exclusivity beyond that date. The company has also defended its intellectual property through litigation. [1]

What side effects are patients asking about?

Patients and caregivers commonly report appetite loss, fatigue, and weight loss with Fintepla. Heart valve monitoring is also required because fenfluramine, the active ingredient, has a history of causing heart valve damage in the früheren weight-loss version of the drug.